Rocket Pharma Surges as FDA Approves Gene Therapy for Rare Immune Disease

Rocket Pharmaceuticals (RCKT) stock rises around 9% in premarket trading after the FDA approves its gene therapy candidate Kresladi for leukocyte adhesion deficiency-I (LAD-I), a rare immune disease. The FDA granted accelerated approval for the treatment.